<?xml version="1.0" encoding="utf-8"?>
			<journal>
			<title>Iranian Journal of Basic Medical Sciences</title>
			<title_fa></title_fa>
			<short_title></short_title>
			<subject>Medical Sciences</subject>
			<web_url>https://ijbms.mums.ac.ir/</web_url>
			<journal_hbi_system_id>0</journal_hbi_system_id>
			<journal_hbi_system_user></journal_hbi_system_user>
			<journal_id_issn>2008-3866</journal_id_issn>
			<journal_id_issn_online>2008-3874</journal_id_issn_online>
			<journal_id_pii></journal_id_pii>
			<journal_id_doi></journal_id_doi>
			<journal_id_iranmedex></journal_id_iranmedex>
			<journal_id_magiran></journal_id_magiran>
			<journal_id_sid></journal_id_sid>
			<journal_id_nlai></journal_id_nlai>
			<journal_id_science></journal_id_science>
			<language>en</language>
			<pubdate>
				<type>jalali</type>
				<year>0</year>
				<month>0</month>
				<day>1</day>
			</pubdate>
			<pubdate>
				<type>gregorian</type>
				<year>2017</year>
				<month>5</month>
				<day>1</day>
			</pubdate>
			<volume>20</volume>
			<number>5</number>
			<publish_type>online</publish_type>
			<publish_edition>1</publish_edition>
			<article_type>fulltext</article_type>
			<articleset><article>
				<language>en</language>
				<article_id_issn></article_id_issn>
				<article_id_issn_online></article_id_issn_online>
				<article_id_pubmed></article_id_pubmed>
				<article_id_pii></article_id_pii>
				<article_id_doi></article_id_doi>
				<article_id_iranmedex></article_id_iranmedex>
				<article_id_magiran></article_id_magiran>
				<article_id_sid></article_id_sid>
				<title_fa></title_fa>
				<title>Effect of rosiglitazone on amyloid precursor protein processing and Aβ clearance in streptozotocin-induced rat model of Alzheimer’s disease</title>
				<subject_fa></subject_fa>
				<subject></subject>
				<content_type_fa></content_type_fa>
				<content_type>Original Article</content_type>
				<abstract_fa><![CDATA[]]></abstract_fa>
				<abstract><![CDATA[Objective(s): Increasing evidence suggests that Alzheimer’s disease (AD) is associated with diabetes. Rosiglitazone, a peroxisome proliferator-activated receptor γ (PPAR-γ) agonist and anti-diabetic agent, may improve symptoms of AD. However, the underlying therapeutic potential of it has not been fully elucidated. Materials and Methods: Rats were divided into four groups: control group, sham operated group, Streptozotocin (STZ) group, rosiglitazone (RGZ) group. Particularly, the STZ-induced rat model was established by intracerebroventricular injection (3 mg/kg) on the first and third day. The water maze behavioral test was performed to evaluate spatial reference learning and memory of the rats. Aβ1-40 and Aβ1-42 levels were measured by ELISA method. To determine APP-derived fragment, BACE1 and Aβ degrading enzymes levels, such as NEP and IDE, as well as Aβ transportation protein level, such as LRP1, RAGE, Abca1 and APOE , which were analyzed by Western blot. Immunohistochemistry was used to observe the change of Aβ1-40 and Aβ1-42 in hippocampus. Results: Chronic treatment with RGZ could reduce the Aβ level and improved spatial memory performance in STZ-induced rat model. However, RGZ modified the expression of specific transport proteins monitoring Aβ clearance, such as ATP-binding cassette transporter 1 (ABCA1), lipoprotein receptor-related protein 1 (LRP1), and the advanced glycation end product-specific receptor (RAGE) rather than change levels of Aβ degrading enzymes, such as IDE and NEP, nor affect APP processing.  Conclusion: As a potential therapeutic strategy, rosiglitazone might exert anti-AD effect not by alteration of APP processing pathway and Aβ degradation directly, but through promotion of Aβ clearance indeed.]]></abstract>
				<keyword_fa></keyword_fa>
				<keyword>Alzheimer’s disease, Amyloid precursor protein processing, β-amyloid peptide clearance, Peroxisome proliferator activated receptor γ</keyword>
				<start_page>474</start_page>
				<end_page>480</end_page>
				<web_url>https://ijbms.mums.ac.ir/article_8669.html</web_url>
			<author_list><author>
				<first_name>Li</first_name>
				<middle_name></middle_name>
				<last_name>Wang</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>emlab9911@163.com</email>
				<code>35522</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Geriatrics, the Second Affiliated Hospital of the Harbin Medical University, Harbin 150081, China</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Wei</first_name>
				<middle_name></middle_name>
				<last_name>Liu</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>weicuic@yeah.net</email>
				<code>35523</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Neurology, Peking University Third Hospital, Beijing 100080, China</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Ying</first_name>
				<middle_name></middle_name>
				<last_name>Fan</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>yingchangguo@yeah.net</email>
				<code>35524</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Geriatrics, the Second Affiliated Hospital of the Harbin Medical University, Harbin 150081, China</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Tingting</first_name>
				<middle_name></middle_name>
				<last_name>Liu</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>tingtinglingc@sina.com</email>
				<code>35525</code>
				<coreauthor>No</coreauthor>
				<affiliation>Department of Geriatrics, the Second Affiliated Hospital of the Harbin Medical University, Harbin 150081, China</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author><author>
				<first_name>Chunjiang</first_name>
				<middle_name></middle_name>
				<last_name>Yu</last_name>
				<suffix></suffix>
				<first_name_fa></first_name_fa>
				<middle_name_fa></middle_name_fa>
				<last_name_fa></last_name_fa>
				<suffix_fa></suffix_fa>
				<email>yuchunjiang123@126.com</email>
				<code>35526</code>
				<coreauthor>Yes</coreauthor>
				<affiliation>Department of Neurology, The Second Affiliated Hospital of the Harbin Medical University, Harbin 150081, China</affiliation>
				<affiliation_fa></affiliation_fa>
				 </author></author_list>
				</article>
			</articleset>
			</journal>